Skip to contentO
Oric Pharmaceuticals, Inc.
O
ORICOric Pharmaceuticals, Inc. Released Aug 10, 2021, after the close
10-Q filed Aug 10, 2021, 41 days after period end · 0000950170-21-001185
Q2 2021 · 10-Q
Revenue—
Net Income-$21.01M-$21.01MN/M vs Q2 2020N/M vs Q1 2021 EPS Diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oric Pharmaceuticals, Inc. · CIK 1796280 · Engraved from SEC EDGAR
-$0.57-$0.57N/M vs Q2 2020N/M vs Q1 2021 Operating Income-$21,057,000N/M Operating Cash Flowderived-$16,214,000N/M Free Cash Flowderived-$16,349,000N/M ended Jun 30, 2021 · filed Aug 10, 2021 · 41 d after period end